Melanin-concentrating hormone (MCH), a neuropeptide expressed in central and peripheral nervous systems, plays an important role in the control of feeding behaviors and energy metabolism. An orphan G protein-coupled receptor (SLC-1͞GPR24) has recently been identified as a receptor for MCH (MCHR1). We report here the identification and characterization of a G protein-coupled receptor as the MCH receptor subtype 2 (MCHR2). MCHR2 has higher protein sequence homology to MCHR1 than any other G protein-coupled receptor. The expression of MCHR2 has been detected in many regions of the brain. In contrast to MCHR1, which is intronless in the coding region and is located at the chromosomal locus 22q13.3, the MCHR2 gene has multiple exons and is mapped to locus 6q21. MCHR2 is specifically activated by nanomolar concentrations of MCH, binds to MCH with high affinity, and signals through Gq protein. This discovery is important for a full understanding of MCH biology and the development of potential therapeutics for diseases involving MCH, including obesity.
M
elanin-concentrating hormone (MCH) is a cyclic neuropeptide originally isolated from the salmon pituitary gland (1) . It regulates skin color in teleost fish by the induction of melanin aggregation in the melanocytes. Mammalian MCH is present in neurons of both the central and peripheral nervous systems, with predominant expression in the lateral hypothalamus and zona incerta (2, 3) . Although MCH has been implicated in a variety of physiological functions, its central role in the control of feeding and energy balance has been the focus of previous studies (reviewed in ref. 4) . When administered centrally, MCH promotes food intake. Its expression in the lateral hypothalamus is induced by starvation (5) . MCH knockout mice are lean and hypophagic and have increased metabolic rates and reduced body weight (6) . Overexpression of MCH in transgenic mice leads to obesity (7) . MCH and components of MCH signaling pathways have therefore become very attractive as potential antiobesity drug targets.
Recently, an orphan G protein-coupled receptor (GPCR) named SLC-1͞GPR24 (8) was identified as a receptor for MCH (MCHR1) (9) (10) (11) (12) (13) . Its expression has been detected in many regions of the brain (8, 9, 11, (13) (14) (15) , including the cortex, hippocampus, thalamus, midbrain, and pons, with relatively high expression levels in the ventromedial, dorsomedial, and arcuate nuclei of the hypothalamus. The distribution of MCHR1 in these areas of the central nervous system is consistent with the involvement of the system in the control of feeding behaviors. Furthermore, MCH has been indicated in a variety of physiological processes in addition to feeding, and circumstantial evidence exists for the possible presence of an additional MCH receptor(s) (16, 17) . In this study, we isolated and identified a MCH receptor (MCHR2). Its expression pattern is similar to that of MCHR1, with high levels in many areas of the brain. It binds to MCH with high affinity and is specifically activated by nanomolar concentrations of the hormone.
Materials and Methods
Sigma-RBI Peptide Library. The library was purchased from Sigma. It contains 60 different bioactive peptides.
GPCR Sequence Searches.
A sequence alignment of the protein sequences of 204 known human GPCRs was used to construct a hidden Markov model (search date was October 19, 2000; refs. 18 and 19) with the use of HMMBUILD of the HMMER 2.1.1 software package (Sean Eddy, Washington University, St. Louis). Highthroughput human genomic sequences deposited in the GenBank database were searched with this hidden Markov model, with the use of HFRAME 2.1.5 software (Paracel) on a hardware accelerator (GeneMatcher, Paracel, Pasadena, CA).
Cloning of the Full-Length cDNA for MCHR2. The MCHR2 cDNA was cloned by 5Ј͞3Ј rapid amplification of cDNA ends (RACE) followed by full-length PCR amplification. For RACE, the Marathon cDNA Racing Kit and human fetal brain Marathon Ready cDNA (CLONTECH) were used according to the kit instructions. For the 5Ј RACE, three primers were used: 5Ј-GATGTTGCCAACCAGCCCTGTTGAA-3Ј, 5Ј-CCCAAT-CATGGAAGGGAGGATGACTG-3Ј, and 5Ј-TTCGGCA-GAGGTGTTCCAACAAGATG-3Ј. For the 3Ј RACE, the following 3 primers were used: 5Ј-TCATGCATCTTGTTG-GAACACCTCTGC-3Ј, 5Ј-CCAGTGTGGTAGATACAGT-CATCCTCCCTTC-3Ј, and 5Ј-GGCTGGTTGGCAACATC-CTCATTGTA-3Ј. The RACE products were sequenced to find the start and stop codons for MCHR2. The start codon was confirmed by the presence of an in-frame stop codon preceding the ATG. The full-length cDNA encoding MCHR2 was then PCR amplified from the same cDNA library with the use of an Advantage 2 High Fidelity PCR Kit (CLONTECH) and primers 5Ј-CACCATGAATCCATTTCATGCATCTTG-3Ј and 5Ј-CAATCATGTCTAGACTCATGGTG-3Ј. The full-length cDNA was cloned into the expression vector pEF6͞V5-His-TOPO or pcDNA3.1͞V5-His-TOPO with the use of a TOPO cloning kit from Invitrogen.
tissues. The multiple tissue RNA array blots used in this study were also from CLONTECH. It contains normalized loadings of mRNA from 76 different human tissues and control RNAs. The human brain RNA blots were purchased from the Biochain Institute. Each lane of the Biochain blots contains 20 g of total RNA isolated from various regions of the human brain. The MCHR2 probe used for Northern and array blot hybridization was a PCR product that includes the entire MCHR2 coding region. The primers used for the PCR amplification of MCHR2 probe were 5Ј-ATGAATCCATTTCATGCATCTTG-3Ј and 5Ј-CA ATCATGTCTAGACTCATGGTG-3Ј. The probe for MCHR1 was a restriction fragment from the MCHR1 expression plasmid pEF6͞V5-MCHR1 that contains the full-length human MCHR1 cDNA. The random primer labeling kit Prime-it II (Stratagene) was used to label the probes for MCHR1 and MCHR2. The hybridization was carried out with the use of the Rapid-hyb buffer system (Amersham Pharmacia). 
Results
Isolation of Full-Length cDNA for MCHR2. By searching human genomic sequences with a GPCR hidden Markov model (Materials and Methods), we identified a sequence encoding part of a putative GPCR. This sequence was found in a BAC clone with the GenBank accession number AC027643. It was later shown to be a MCH receptor, so we designate it as MCHR2. BLAST searches with this partial MCHR2 sequence revealed that it was a gene with no expressed sequence tag or protein matches. The closest known homolog was the initially described MCH receptor, followed by the somatostatin and opioid receptors (Fig. 1A) .
The full-length MCHR2 cDNA was cloned by 5Ј and 3Ј RACE. After identifying the start and stop codons of MCHR2 by sequencing the RACE products, we cloned the full-length cDNA by PCR, with the use of a human brain cDNA library as the template. Analysis of the protein sequence encoded by the full-length MCHR2 cDNA confirmed that it was most similar to the MCH receptor (Fig. 1 A) . MCHR2 has an overall amino acid identity of 36% with MCH receptor protein and a 44% amino acid identity in the transmembrane regions. It shares 39% amino acid identity with somatostatin receptor 1 (SSTR1) in the transmembrane regions and a 32% identity to SSTR1 over 312 aa (Fig. 2B) . It is worth noting that the second and third intracellular loops of MCHR2 are rather divergent from those of MCHR1 and SSTR1. There is an insertion of six amino acids in the third intracellular loop of MCHR2 compared with MCHR1 and SSTR1. The gene structure and the chromosome location were determined by comparison of the cloned cDNA sequence to the genomic sequence in the BAC clone (AC027643). In contrast to MCHR1, which is intronless in the coding region located at chromosomal locus 22q13.3, MCHR2 has five coding exons and one noncoding exon that are at locus 6q21 (Fig. 1C) . Furthermore, two representatives of an alternatively spliced MCHR2 mRNA were found by sequencing RACE products. This splice form has an extended fifth exon and lacks the sixth exon, giving rise to a predicted protein sequence that lacks the last two transmembrane domains ( Fig. 1 B and C ; the arrow in B indicates the end of the putative truncated protein).
Tissue Distribution of MCHR2. The expression of MCHR2 was analyzed by Northern hybridization, RNA dot array blot hybridization, and reverse transcription-PCR. By Northern hybridization with MCHR2 cDNA as a probe, a single species of mRNA with an estimated size of 3.0 kb was detected specifically in the brain (Fig. 2 A) . MCHR2, like MCHR1, is widely distributed in the brain. Its expression was detected in most of the brain regions checked (Fig. 2 B and C and RNA dot array hybridization, result not shown), including frontal lobe, temporal lobe, occipital lobe, precentral gyrus, pons, hippocampus, amygdala, putamen, and the caudate nucleus, with relatively high levels in the cerebral cortex. Lower levels of expression were also detected in thalamus, corpus callosum, and medulla oblongata. No clear signal was detected in cerebellum or spinal cord. Expression of MCHR2 was also detected in hypothalamus (Fig. 2C) , adipocytes (very weak band), pituitary, and pancreas (data not shown). We detected the alternatively spliced short form of MCHR2 mRNA only by RACE-PCR and not by Northern hybridization, indicating a very low level of expression. In summary, MCHR2 appears to be expressed predominantly in the brain, with no dramatic differences observed from the expression pattern of MCHR1 in the central nervous system. in the MCHR2 transfected cells is MCH concentration dependent (Fig. 3 A and  B) , with an EC 50 of 2.10 nM in HEK293 cells. The EC 50 for MCHR1 under similar conditions was 14.4 nM. To clearly determine the specificity of MCHR2, we tested several MCHrelated peptides for agonist activity. Salmon MCH has a high degree of homology to the human MCH (4) and activates MCHR1 (9) . It also activates MCHR2 (Fig. 3C) . [Phe 13 , Tyr   19 ]-MCH, a synthetic analog of MCH known to bind to and activate MCHR1 (8, 12, 22) , also activates MCHR2, with a slightly lower potency compared with MCH. Other peptides from the same MCH precursor neuropeptide-EI and neuropeptide GE (23, 24) were inactive for MCHR2. Because MCHR1 and MCHR2 share relatively high homology with the somatostatin receptors, we Fig. 1 . Analysis of the sequences, genomic structure, and splicing of the MCHR2 gene. (A) Sequence similarity between MCHR2 and related GPCRs. The protein sequence of MCHR2 was aligned with the GPCRs most similar to it, including all of the members of the somatostatin and opioid receptor families and two orphan GPCRs, GPR7 and GPR8. The GCG programs DISTANCES and GROWTREE were used to generate a similarity tree based on the alignment. The lengths of the horizontal line segments connecting two GPCRs are inversely proportional to the similarities between their protein sequences. tested somatostatin-14, somatostatin-28, somatostatin analog, RC-160, and two peptides structurally very similar to somatostatin, cortistatin-14 and cortistatin-29 (25) . None of these peptides showed any activity on MCHR2 at concentrations up to 1 M. Finally, ␣-melanotropin, a functional antagonist of MCH (26) (27) (28) (29) , was also inactive on MCHR2 as an agonist.
We analyzed the binding of MCHR2 to radiolabeled MCH in a receptor-binding assay (Materials and Methods). Membranes were prepared from HEK293 cells that were transiently transfected with pEF6͞V5-MCHR2. Specific binding of , and this effect was insensitive to PTX treatment (Fig. 5 A and B) . In contrast, the Ca 2ϩ response in cells transfected with MCHR1 was mostly inhibited, which is consistent with previous reports (30) . Lysophosphatidic acid (LPA) (31) and ADP (32) , which stimulate Ca 2ϩ increase through endogenous Gi and Gq receptors, respectively, were tested as controls. As expected, the LPAinduced Ca 2ϩ response was PTX sensitive, whereas the ADPinduced response was resistant. Similar results were also obtained with CHO cells. These results suggested that MCHR2 is primarily coupled to Gq, which is in contrast with the findings for MCHR1, which has been shown to couple to multiple G proteins, including Gi, Go, and Gq (30). 
Discussion
MCH plays roles far beyond the one originally discovered in the regulation of skin color in teleost fish (1) . It has been shown to regulate the hypothalamo-pituitary-adrenal axis (33), modulate water and electroyte fluxes in the gastrointestinal tract (34), stimulate oxytocin secretion (35) , regulate sensory processing (36) , and modulate the activity of monoaminergic systems (37). Its critical role in feeding behaviors and energy balance, however, has been the most and the best characterized so far (4) (5) (6) (7) 26) . One MCH receptor, MCHR1, has recently been identified, and it is believed to be the key mediator of MCH activities (9) (10) (11) (12) (13) . MCHR1 mRNA is present in many different regions of the brain. Relatively high levels of expression of MCHR1 have been observed in the ventromedial, dorsalmedial, and arcuate nuclei of the hypothalamus, regions that are known to play an important role in feeding behaviors (15, 38, 39) . Recently, it has been shown that MCHR1 is a target of leptin, and overexpression of MCH in transgenic mice causes obesity (7, 15) . Because MCH exerts a wide variety of effects, and GPCRs often have multiple subtypes that are involved in different processes, there was a possibility of additional MCH receptor(s). Circumstantial evidence did support such a possibility. For example, MCH seems to specifically bind to several cell lines, B16F1 melanoma cells and the SVK14 keratinocytes, which do not express MCHR1 (4, 16, 17) . We searched the genomic databases (search date was October 19, 2000) for sequences that have high similarity to that of the MCHR1 and identified a MCH receptor. It would be interesting to determine whether MCHR2 is expressed in these cells.
The tissue distribution of MCHR2 mRNA is very similar to that of MCHR1 (Fig. 2 A and B) . Both are expressed in many regions of the brain, including the hypothalamus. MCHR2 expression has also been detected in a few other tissues that have been reported to express MCHR1, including adipose tissue (40) and pituitary (14) . With such similar expression patterns for these two receptors, they are likely to both be important in mediating MCH effects, including modulation of feeding and energy balance. Despite the similarities, there may still be unobserved differences in the expression patterns of the two receptors. For example, it is quite possible that MCHR1 and MCHR2 might be expressed in different types of cells within the same tissue and͞or have polarized localization in the same cell (41) . A detailed comparative analysis of the localization of MCHR1 and MCHR2 by in situ hybridization and immunohistochemistry is needed. Furthermore, expression of the truncated MCHR2 splice form could also modulate the activity of the MCHR1 or MCHR2 receptors through heterodimerization. The expression pattern of this alternative splice form of MCHR2 is unclear, however. It is also noteworthy that the overall homology between MCHR2 and MCHR1 (36%) is relatively low for a family of receptors that bind to the same ligand and that the genomic structures of the two genes are very different. These indicate that they are more divergent in evolution than some other GPCR family members. It should not be surprising that additional ligand(s) might be found for MCHR2 and that MCHR2 might play a biological role rather different from that played by MCHR1.
MCHR1 has been shown to couple to Gi, Go, and Gq, whereas MCHR2 primarily couples to Gq. In our assays, the Ca 2ϩ response and production of inositol phosphates upon stimulation with MCH in cells transfected with MCHR2 is completely resistant to PTX. Activation of different G proteins triggers different downstream responses in cells. Thus the difference in G protein coupling of MCHR1 and MCHR2 may mediate different effects on cells. The relative expression levels or activities of the two receptors in a cell may determine how it responds to MCH. The second and third intracellular loops of MCHR2 are rather divergent from that of MCHR1 and SSTRs, both of which are similarly coupled to multiple G proteins. This sequence divergence may be responsible for the difference in G protein coupling of MCHR2, because the intracellular loops, the third loop in particular, have been implicated in G protein coupling in other GPCRs (42) .
The discovery of a MCH receptor provides a tool essential to a full understanding of the complex biology of MCH. It will also play an important role in the development of subtype-specific agonists and antagonists that is useful for the study of physiological functions and therapeutic applications involving MCH.
